Skip to main content

A Survey of Recent Patents on CB2 Agonists in the Management of Pain

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

Pain, a homeostatic and protective mechanism which can go awry in disease states and therefore needs treatment, is a complex and differentiated sensorial perception which may be classified as physiological, inflammatory and neuropathic. Chronic pain represents a major health problem throughout the world, thus several companies and researchers have embarked on the search for new drugs and targets to treat the disease. The different types of receptors in the CNS involved in the mediation of analgesia include the cannabinoid receptors: in particular, CB2 modulators seem to represent a new potential class of analgesic. This review covers recent patents and advances in CB2 agonist studies in the management of pain.





Keywords: Azacycloalkane Carboxamides; BOEHRINGER INGELHEIM; Biphenylmethyl Ethyl Ureas; CARA THERAPEUTICS; CB2 receptor ligands; CB2 receptors; Cannabinoid; chronic pain; inflammatory pain; neuropathic pain

Document Type: Research Article

DOI: https://doi.org/10.2174/157488912798842214

Publication date: 2012-04-01

More about this publication?
  • Recent Patents on CNS Drug Discovery publishes review articles on recent patents in the field of CNS drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on CNS drug discovery is also included in the journal. The journal is essential reading for all researchers involved in CNS drug design and discovery.
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more